Roche Holdings AG Basel ADR (RHHBY) Given Consensus Recommendation of “Hold” by Analysts
Shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) have been given a consensus rating of “Hold” by the eleven analysts that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $34.50.
A number of research firms have recently weighed in on RHHBY. ValuEngine downgraded shares of Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a research note on Tuesday, August 7th. Wolfe Research began coverage on shares of Roche Holdings AG Basel in a research note on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Cowen reaffirmed a “buy” rating and issued a $34.00 price target on shares of Roche Holdings AG Basel in a research note on Thursday, July 26th. Bank of America downgraded shares of Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a research note on Monday, September 10th. Finally, Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 price target on the stock in a research note on Wednesday, September 12th.
OTCMKTS:RHHBY traded up $0.30 during trading hours on Monday, hitting $31.30. 934,736 shares of the stock traded hands, compared to its average volume of 1,478,028. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.53. Roche Holdings AG Basel has a fifty-two week low of $26.30 and a fifty-two week high of $32.42. The company has a market cap of $210.60 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 1.87 and a beta of 0.53.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.
Read More: Benefits of owning preferred stock
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.